Actively Recruiting

Age: 0 - 36Months
All Genders
Healthy Volunteers
ID05971446

Visual Function as a Novel Outcome Measure Following Neonatal Hypoxic Ischemic Encephalopathy

Led by University of Wisconsin, Madison · Updated on 2026-05-14

125

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

U

University of Wisconsin, Madison

Lead Sponsor

M

Meriter Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to better understand how eye injuries relate to a baby's future development, focusing on babies with hypoxic-ischemic encephalopathy (HIE). The study explores whether eye function tests and brain test results can improve diagnosis and treatment for these babies. It is a longitudinal observational study that tracks visual and brain outcomes in children with HIE compared to healthy babies. Participants will undergo eye exams including Visual Evoked Potential (VEP) and Electroretinogram (ERG) tests. These involve placing electrodes on the head or skin around the eyes while exposing the eyes to light flickers. Each eye is tested separately, and some babies without HIE are also tested as a comparison group. Data will be collected at birth and multiple points up to 36 months of age. During the study, babies will have up to two eye exam sessions and their neurodevelopment and neuroimaging outcomes will be monitored through 30 months of life. Researchers will analyze eye function, brain imaging, and developmental tests to find correlations. The goal is to develop new, noninvasive tools that help improve long-term outcomes for babies affected by HIE.

CONDITIONS

Brief Title

Healthy Little Eyes

Who Can Participate

Age: 0 - 36Months
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) who are less than 78 hours old at enrollment
  • Pediatric patients under 36 months of age with a diagnosis of HIE presenting to follow-up clinics
  • Healthy newborns in the Newborn Nursery who are at least 37 weeks and less than 42 weeks gestational age
  • Healthy newborns with a 5-minute Apgar Score of 7 or higher
  • Healthy newborns with head circumference within average limits (between 3rd and 97th percentile)
  • Parent or legal guardian able to complete consenting process in English
Not Eligible

You will not qualify if you...

  • Babies with prenatally diagnosed or congenital brain or eye abnormalities unrelated to HIE, such as microphthalmia, anophthalmia, congenital cataract, coloboma, congenital glaucoma, CMV retinitis, optic nerve hypoplasia, aniridia, cryptophthalmos, globe abnormalities, or nystagmus
  • Known central nervous system illness other than HIE, including congenital brain malformations or hydrocephalus
  • Participants whose parent or legal guardian cannot provide informed consent, including those in foster care, state custody, or with minor parents
  • Healthy newborns admitted to NICU for any reason
  • Healthy newborns with known genetic abnormalities, diagnosed HIE, hypoglycemia, hyperbilirubinemia requiring phototherapy, prenatal exposure to substances, neonatal infections requiring treatment, TORCH infections, abnormal hearing or toxicology screens
  • Newborns identified as large or small for gestational age
  • Cases where attending medical team does not approve participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 78 hours for neonates with HIE, or at birth for healthy newborns

Participants are screened for eligibility to participate in the trial.

1 screening visit (in-person)

Diagnostic Evaluation

Duration - Within the first 5 days of life for neonates, and at birth for healthy newborns

Participants undergo visual function tests including Visual Evoked Potential (VEP) and Electroretinogram (ERG) to assess retinal and visual cortical function.

1 to 2 visits depending on cohort assignment

Long-term Monitoring

Duration - Up to 30 months

Participants have follow-up assessments of visual function and neurodevelopmental outcomes through 30 months of life.

Multiple visits around 3, 9, 18, and 30 months of life

Trial Site Locations

Total: 1 location

1

University of Wisconsin

Madison, Wisconsin, United States, 53705

Actively Recruiting

Loading map...

Research Team

A

Alexandra Lindstrom

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Phase IIb Dose Escalation Study of Levetiracetam for the T...

Neonatal Seizure

Actively Recruiting

5 locations

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study...

Hypoxic-Ischemic Encephalopathy

Actively Recruiting

15 locations

Against Chikungunya Virus and Neonatal Infection

Chikungunya Virus Infection

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here